Clinical trial · no report yet · Phase 2
HER2CLIMB-04
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- NCT04539938 ↗
- Completed
- Seagen, a wholly owned subsidiary of Pfizer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- tucatinib; trastuzumab deruxtecan
- Arms
- Single Arm · Experimental
- Enrollment
- 70
- Primary outcomes
- Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Dec 1, 2020
- Primary completion
- Jul 15, 2024
- Results posted
- Yes
- Registry record
- NCT04539938 · updated Mar 23, 2026
Publications
linked from the registry- Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton EP. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026 Aug;26(8):21-30. doi: 10.1016/j.clbc.2026.05.010. Epub 2026 Jul 10. PubMed 42431148